Ideally : Actualité Ideally en direct - P2 | Bourse Reflex
Accueil > Tags > Ideally

  • Toutes les actualités en rapport avec « Ideally »

28/07 18:00 Ideally - Business Update - Second Quarter 2015

28/07 08:00 Ideally - TRONICS AND THALES TEAM UP TO QUALIFY THE STANDARD PRODUCT GYPRO3300 FOR CIVIL AVIATION APPLICATIONS

27/07 10:15 Ideally - FINANCIAL YEAR 2014/15 REVENUE

07/07 18:00 Ideally - Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

03/07 18:00 Ideally - Summary of Genticel's liquidity contract with Oddo Corporate Finance

02/07 18:15 Ideally - Genticel CFO, Martin Koch, Appointed CEO to Replace Benedikt Timmerman during Temporary Medical Leave of Absence

16/06 07:00 Ideally - Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

10/06 07:00 Ideally - Usine IO, the product prototyping and innovation platform, opens its capital to "French Tech Accélération" and Prodways Entrepreneurs

08/06 18:00 Ideally - 2014-2015 ANNUAL RESULTS : Strong increase in profitability Group net profit: +55%

01/06 07:00 Ideally - Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform

21/05 18:00 Ideally - Documents Available for Annual General Meeting of Shareholders

28/04 19:00 Ideally - Business Update - First Quarter 2015

23/04 18:00 Ideally - Genticel to Participate in SmallCap Event on April 27 - 28 in Paris, France

20/04 18:40 Ideally - Genticel to Present Further Promising Pharmacology In-Vivo Results of its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015

09/04 19:20 Ideally - Genticel strengthens management team and appoints Valerie Leroy as Senior Director, Corporate Communications and Investor Relations

01/04 17:00 Ideally - 2014 Reference Document Available with Annual Financial Report

06/03 18:00 Ideally - Implementation of a Programmed Trading Mandate

02/03 19:00 Ideally - 2014 Annual Results

05/02 16:30 Ideally - Genticel presents pipeline development in EUROGIN congress held in Seville, Spain - 4 to 7 February 2015

02/02 18:30 Ideally - Genticel licenses Vaxiclase platform to Serum Institute of India for use in pertussis vaccines